Underlying conditions such as hypothyroidism, Cushing's syndrome, PCOS, or obstructive sleep apnoea can blunt weight loss responses and should be investigated if not already excluded
GLP-1 17,1%, 22,7%, 12,2%
Fact : Actually, these drugs are very safe as proven by extensive clinical testing
The most commonly reported problem is skin irritation redness, itching, or a mild rash where the patch sits, particularly with prolonged use or if the adhesive contacts sensitive skin
The short version: injection format is confirmed
Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes